# Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer

> **NCT02899078** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, Davis** · enrollment: 31 (actual)

## Conditions studied

- Metastatic Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** Ibrutinib
- **DRUG:** Nivolumab

## Key facts

- **NCT ID:** NCT02899078
- **Lead sponsor:** University of California, Davis
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-11-15
- **Primary completion:** 2020-08-05
- **Final completion:** 2021-02-24
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2025-05-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02899078

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02899078, "Ibrutinib and Nivolumab in Treating Patients With Previously-Treated Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02899078. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*